CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Revenues:
Total revenues	$ 5,389,089	$ 3,903,343
Cost of revenues	877,613	1,206,814
Operating expenses:
Selling, general and administrative	10,278,045	11,043,463
Research and development	2,967,278	2,751,578
Depreciation and amortization	390,424	547,796
Total operating expenses	13,635,747	14,342,837
LOSS FROM OPERATIONS	(9,124,271)	(11,646,308)
Other (expense) income:
Interest (expense) income, net (including related party interest of $46,586 and $5,844 for the years ended September 30, 2019 and 2018, respectively)	(162,432)	(9,615)
Other expense, net	(43,299)	(37,005)
Loss on extinguishment of debt	(1,260,399)	0
Unrealized gain on change in fair value of secured convertible notes payable	1,972,955	0
Loss before provision for income taxes	(8,617,446)	(11,692,928)
Provision for income taxes	15,000	0
NET LOSS	(8,632,446)	(11,692,928)
Less: Net loss attributable to noncontrolling interest	9,323	0
NET LOSS attributable to Applied DNA Sciences, Inc.	(8,623,123)	(11,692,928)
Deemed dividend related to warrant modifications	(309,607)	0
NET LOSS applicable to common stockholders	$ (8,932,730)	$ (11,692,928)
Net loss per share applicable to common stockholders-basic and diluted	$ (9.69)	$ (15.86)
Weighted average shares outstanding-basic and diluted (in shares)	921,809	737,441
Product
Revenues:
Total revenues	$ 2,136,055	$ 1,827,626
Service
Revenues:
Total revenues	$ 3,253,034	$ 2,075,717